GeneFab
Alameda, CA and South San Francisco
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
61.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: GeneFab
- Signal Score
- 61.5/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- Alameda, CA and South San Francisco
- Founded
- 2023
- Max Bioreactor Scale
- 200L
- Website
- https://www.genefab.com
- Modalities
- Cell Therapies, Autologous therapies, Allogeneic therapies, Stem cell therapies, Gene-Modified Cell Therapy, Lentiviral, gamma-retroviral
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About GeneFab
Examples of our GMP manufacturing support and strategic partnerships: GeneFab conducts the clinical manufacturing of Senti Bio’s chimeric antigen receptor natural killer (CAR-NK) medicines pipeline, SENTI-202. https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-closing-transaction-leveraging-its-cmc; and Patnership with RegCell to advance their regulatory T cell (Treg) therapies for autoimmune diseases, https://www.outsourcedpharma.com/doc/genefab-regcell-announce-partnership-advance-autoimmune-cell-therapy-clinical-trials-0001
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapies, Autologous therapies, Allogeneic therapies, Stem cell therapies, Gene-Modified Cell Therapy, Lentiviral, gamma-retroviral
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
63.0
Capacity status: Available
StatusAvailable
Frequently Asked Questions About GeneFab
What is GeneFab's CDMO Signal Score?
GeneFab has a Signal Score of 62/100, based on quality, operations, financial stability, and capacity data.
Evaluating GeneFab for a manufacturing program?
Use the free AI matchmaker to compare GeneFab against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
August Bioservices
San Carlos, CA
Signal Score: 77.5
AAV, Lentiviral
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 74.5
mRNA, Gene Therapy, Cell Therapy, Lentiviral
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA